The in vivo anti-tumor efficacy of GNUV201 was evaluated using MC38 colorectal cancer, B16F10 melanoma, and Pan02 pancreatic cancer model in C57BL/6 mouse (Fig. 5a-c) and MC38 colorectal cancer model in hPD-1 KI mice (Fig. 5d). This evidence concerns the gene PDCD1 and familial pancreatic carcinoma.